- Home
- ANIP vs CDTX Comparison
ANIP vs CDTX Comparison
Compare ANIP & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- CDTX
- Stock Information
- Founded
- ANIP 2001
- CDTX 2012
- Country
- ANIP United States
- CDTX United States
- Employees
- ANIP N/A
- CDTX 73
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIP Health Care
- CDTX Health Care
- Exchange
- ANIP Nasdaq
- CDTX Nasdaq
- Market Cap
- ANIP 2.0B
- CDTX 1.6B
- IPO Year
- ANIP N/A
- CDTX 2015
- Fundamental
- Price
- ANIP $98.30
- CDTX $64.73
- Analyst Decision
- ANIP Strong Buy
- CDTX Strong Buy
- Analyst Count
- ANIP 9
- CDTX 11
- Target Price
- ANIP $86.00
- CDTX $57.00
- AVG Volume (30 Days)
- ANIP 488.4K
- CDTX 489.9K
- Earning Date
- ANIP 11-07-2025
- CDTX 11-06-2025
- Dividend Yield
- ANIP N/A
- CDTX N/A
- EPS Growth
- ANIP N/A
- CDTX N/A
- EPS
- ANIP N/A
- CDTX N/A
- Revenue
- ANIP $747,399,000.00
- CDTX N/A
- Revenue This Year
- ANIP $39.32
- CDTX N/A
- Revenue Next Year
- ANIP $9.62
- CDTX N/A
- P/E Ratio
- ANIP N/A
- CDTX N/A
- Revenue Growth
- ANIP 38.68
- CDTX N/A
- 52 Week Low
- ANIP $52.50
- CDTX $10.14
- 52 Week High
- ANIP $99.50
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- ANIP 77.93
- CDTX 56.75
- Support Level
- ANIP $96.50
- CDTX $61.10
- Resistance Level
- ANIP $99.50
- CDTX $65.84
- Average True Range (ATR)
- ANIP 2.17
- CDTX 3.00
- MACD
- ANIP -0.33
- CDTX -0.46
- Stochastic Oscillator
- ANIP 87.17
- CDTX 62.97
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.